Softwr

Healthcare · head to head

Fullscript vs Paige

Fullscript logo

Fullscript

Healthcare

Supplement dispensing for practitioners, free to use because it earns on the products

From
Free
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only Fullscript has a free tier, so it costs nothing to try first.
  • Each has a real cost: Fullscript the practitioner sets their own margin on products they clinically recommend, which is a conflict of interest that some professional bodies and patients view badly, and the platform makes the arrangement easy rather than making it visible.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Fullscript covers Protocol dispensing, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Fullscript and Paige actually diverge.

Attributes where Fullscript and Paige differ
AttributeFullscriptPaige
Starting priceFreeOn request
Pricing modelPer user per monthquote
Free tierYesNo
PlatformsWeb, iOS, AndroidWeb, Cloud, On-premise

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Fullscript

  • Protocol dispensing
  • Profit dispensary
  • Auto refill
  • Lab ordering
  • Patient app
  • EHR integration
  • Enterprise catalogue control

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Fullscript

  • A functional medicine practice that wants to stop holding supplement stock, cash and expiry risk in the clinicnot Paige
  • A dietitian or naturopath adding a dispensary revenue stream without buying inventory upfrontnot Paige
  • A clinic that needs patients to actually keep taking a protocol, where auto refills and dose reminders address the adherence problem directlynot Paige
  • A multi site integrative health group that wants a single approved catalogue rather than each clinician choosing their own brandsnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Fullscript
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Fullscript
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Fullscript
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Fullscript

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Fullscript

  • The practitioner sets their own margin on products they clinically recommend, which is a conflict of interest that some professional bodies and patients view badly, and the platform makes the arrangement easy rather than making it visible.
  • The account is free but the practice does not control pricing, catalogue, shipping cost or the patient discount, so the entire economics of the dispensary can be changed by the vendor without the practice having any lever.
  • Converting to a profit account requires personal identity verification, tax details and a bank account, and makes dispensary earnings the practitioner personal taxable income to report, which is administrative work no one warns about at signup.
  • Product availability and shipping are geographically limited, so practices outside the supported countries cannot use it at all and cross border patients will find items unavailable at checkout.
  • Patient refill schedules, plan history and a slice of practice revenue accumulate inside a platform the practice cannot export in a form another dispensary would accept, so switching later means asking every patient to re-enrol somewhere else.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Fullscript

Free
  • PractitionerFree
    • Full catalogue and dispensing at no account fee
    • Lab ordering and results
    • Standard EHR integrations
  • PatientFree
    • No account fee
    • Mobile app with dose reminders
    • Auto refills, cancellable at any time
  • Enterprise$undefined/year
    • Quoted for health systems and multi site groups
    • Centrally managed catalogue with quality standards
    • API level EHR integration

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Fullscript if

  • You need protocol dispensing.
  • You want to start without paying.
  • You work on Web, iOS, Android.
  • You also want profit dispensary.
Fullscript review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Fullscript or Paige better?
Neither clearly leads. Fullscript starts at Free and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Fullscript or Paige?
Fullscript has a free tier; the other does not. Paid plans start at Free for Fullscript and On request for Paige.
Does Fullscript or Paige run on more platforms?
Fullscript runs on Web, iOS, Android. Paige runs on Web, Cloud, On-premise.
Can I use Fullscript for free?
Yes. Fullscript has a free tier, so you can try it without paying. Paige starts at On request.
What is Fullscript best used for?
Fullscript is most often used for a functional medicine practice that wants to stop holding supplement stock, cash and expiry risk in the clinic, a dietitian or naturopath adding a dispensary revenue stream without buying inventory upfront, a clinic that needs patients to actually keep taking a protocol, where auto refills and dose reminders address the adherence problem directly, a multi site integrative health group that wants a single approved catalogue rather than each clinician choosing their own brands. Of those, a functional medicine practice that wants to stop holding supplement stock, cash and expiry risk in the clinic and a dietitian or naturopath adding a dispensary revenue stream without buying inventory upfront are not what Paige is typically brought in for.
What can Fullscript do that Paige cannot?
Fullscript covers Protocol dispensing, Profit dispensary, Auto refill, Lab ordering. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Fullscript: Is Fullscript really free for practitioners?

Yes, the account has no fee. Fullscript earns on the supplements sold through it, and a practitioner on a profit account also earns a margin on those sales.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Fullscript: How do practitioners make money on it?

By converting to a profit dispensary and setting a margin. That requires tax information and a bank account, and the earnings are taxable income.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Fullscript: What do patients pay?

No account fee, and a ten per cent discount on orders if the practitioner runs a no profit dispensary rather than taking a margin.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Fullscript: Is there an enterprise option?

Yes, quoted for health systems, adding central catalogue control, API EHR integration and cross site reporting.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Fullscript

More on Paige

Keep looking

Other head to heads